---
title: "Cambium Bio Director Increases Stake Through Share Placement"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/280261825.md"
description: "Cambium Bio Limited's director, Yu-Hung Sebastian Tseng, has increased his stake through a share placement, acquiring 4,363,637 shares via Zheng Yang Biomedical Technology Limited, raising its total to 10,862,136 shares. Tseng's direct holding remains unchanged. This move indicates strengthened insider alignment with the company's future. The latest analyst rating for Cambium Bio (AU:CMB) is a Hold with a price target of A$0.46. The company operates in the biotechnology sector, focusing on advanced biomedical technologies, with a current market cap of A$13.12M."
datetime: "2026-03-24T05:47:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280261825.md)
  - [en](https://longbridge.com/en/news/280261825.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280261825.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/280261825.md) | [繁體中文](https://longbridge.com/zh-HK/news/280261825.md)


# Cambium Bio Director Increases Stake Through Share Placement

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Regeneus Ltd. ( (AU:CMB) ) has provided an update.

Cambium Bio Limited has disclosed a change in director Yu-Hung Sebastian Tseng’s interests following a recent share placement. Tseng, who holds shares directly and through Zheng Yang Biomedical Technology Limited, increased his indirect holding as part of the company’s capital-raising activities.

Under the transaction, Zheng Yang Biomedical Technology Limited acquired 4,363,637 ordinary shares at $0.55 each, lifting its stake to 10,862,136 shares, while Tseng’s direct holding remained unchanged. The acquisition, issued via a placement announced in January 2026, consolidates Tseng’s exposure to Cambium Bio and signals strengthened insider alignment with the company’s future performance.

The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.

**More about Regeneus Ltd.**

Cambium Bio Limited, formerly associated with Regeneus Ltd., operates in the biotechnology and biomedical sector. The company’s activities involve advanced biomedical technologies, with equity holdings including stakes held through Zheng Yang Biomedical Technology Limited, reflecting a capital structure typical of clinical- and research-focused biotechs.

**Average Trading Volume:** 11,883

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$13.12M

Learn more about CMB stock on TipRanks’ Stock Analysis page.

### 相关股票

- [Cambium Networks (CMBM.US)](https://longbridge.com/zh-CN/quote/CMBM.US.md)
- [CAMBIUM NETWORKS CORPORATION (CMBMF.US)](https://longbridge.com/zh-CN/quote/CMBMF.US.md)

## 相关资讯与研究

- [Upstream Bio Launches $150 Million At-The-Market Program](https://longbridge.com/zh-CN/news/280691247.md)
- [Climb Bio Consolidates Financial Leadership After SVP Departure](https://longbridge.com/zh-CN/news/281661161.md)
- [Bio-Techne’s New COMET Spatial Tools Might Change The Case For Investing In Bio-Techne (TECH)](https://longbridge.com/zh-CN/news/281130215.md)
- [Anthropic buys biotech startup Coefficient Bio in $400M deal: reports](https://longbridge.com/zh-CN/news/281660846.md)
- [Advanced Biomed Announces Leadership Changes and Board Appointment](https://longbridge.com/zh-CN/news/281088579.md)